Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease

<div>Detection of anti-NDV antibody titer by HI at 7, 14, 21, and 28 days after immunization. Data were analyzed and expressed as mean ± SD, <sup>#</sup><i>P</i> &lt; 0.05, <sup>##</sup><i>P</i> &lt; 0.01 vs rClone30-VP2L-treated chickens and expressed as mean ± SD, <sup>∗∗</sup><i>P</i> &lt; 0.01 vs rClone30-treated chickens.</div>

Transboundary and Emerging Diseases

fig6

Figure 6

Figure 6: Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease 